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characterization of human 
pluripotent stem cell-derived 
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Huanqi Zhu1,2,*, Kelsey S. Scharnhorst1,2, Adam Z. Stieg2,3, James K. Gimzewski1,2,3,4, 
Itsunari Minami5, Norio Nakatsuji5,6, Haruko Nakano7,* & Atsushi Nakano4,7,8,9
Stem cell-derived cardiomyocytes provide a promising tool for human developmental biology, 
regenerative therapies, disease modeling, and drug discovery. As human pluripotent stem cell-derived 
cardiomyocytes remain functionally fetal-type, close monitoring of electrophysiological maturation is 
critical for their further application to biology and translation. However, to date, electrophysiological 
analyses of stem cell-derived cardiomyocytes has largely been limited by biologically undefined 
factors including 3D nature of embryoid body, sera from animals, and the feeder cells isolated from 
mouse. Large variability in the aforementioned systems leads to uncontrollable and irreproducible 
results, making conclusive studies difficult. In this report, a chemically-defined differentiation 
regimen and a monolayer cell culture technique was combined with multielectrode arrays for 
accurate, real-time, and flexible measurement of electrophysiological parameters in translation-ready 
human cardiomyocytes. Consistent with their natural counterpart, amplitude and dV/dtmax of field 
potential progressively increased during the course of maturation. Monolayer culture allowed for the 
identification of pacemaking cells using the multielectrode array platform and thereby the estimation 
of conduction velocity, which gradually increased during the differentiation of cardiomyocytes. Thus, 
the electrophysiological maturation of the human pluripotent stem cell-derived cardiomyocytes in our 
system recapitulates in vivo development. This system provides a versatile biological tool to analyze 
human heart development, disease mechanisms, and the efficacy/toxicity of chemicals.
The potential of human pluripotent stem cells (hPSC) to self-renew indefinitely and differentiate into virtually 
any cell type makes them a valuable cell source for human developmental biology, cell-based regenerative ther-
apy, disease modeling, and drug discovery/assessment1–7. As the human heart is the least regenerative of tissues, 
cardiomyocytes derived from human embryonic stem cell/induced pluripotent stem cells (hESC/iPSC-CMs) pro-
vide a particularly powerful biological tool8–13. Differentiation protocols have evolved over the years to allow for 
large-scale induction of human cardiomyocytes, and efforts have been made to induce further maturation of ESC/
iPSC-CMs in vitro, with tissue engineering approaches showing promising results14–17. However, the maturity of in 
vitro hESC/iPSC-CMs still remains fetal-type with limited electromechanical properties. Unlike postnatal cardio-
myocytes, hESC/iPSC-CMs are proliferative14,18–20, but with immature sarcomere structure18–20 and Ca2+ handling 
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properties14,21–24. Sarcolemmal-dependency of calcium kinetics, negative force-frequency relation21 and high max-
imum diastolic potential demonstrate the functional immaturity of hESC/iPSC-CMs. Indeed, contractile forces 
generated by hESC/iPSC-CMs are estimated to be less than 0.5–5% of cardiomyocytes isolated from the neonatal 
heart25,26. Application of external biophysical cues including mechanical force14, electrical stimulation17, and matrix 
stiffness13,27 are promising approaches to induce the maturation of hESC/iPSC-CMs. However, these approaches 
have yet to achieve sufficient functionality to replace the damaged cardiomyocytes in the diseased heart.
Following the induction of the cardiac gene program during early embryogenesis, cardiomyocytes undergo a 
remarkable maturation process to develop into structurally and functionally competent cardiomyocytes during 
fetal stages, characterized by the assembly of contractile proteins into myofibrillar structure, expression of ion 
channels and gap junctions at the right location, organization of mitochondria and SR along the myofibrils, etc. 
The study of late-stage cardiogenesis is translationally relevant, as most of the events leading to congenital heart 
anomalies occur at later stages, and cell therapy requires functional cardiomyocytes with strong contractile force. 
Although great progress has been made in studies of specification and multilineage differentiation of cardiac 
progenitors, our understanding of the cardiac maturation process remains primitive28. While the differentiation 
level of early cardiac progenitors is well defined by marker gene expression, the maturity of cardiomyocytes at late 
developmental stages is relatively less reflected in the gene expression pattern29–32. Given that the biophysical cues 
are not only the results but also the essential drivers of the cardiac maturation13,27,33–35, the electrophysiological 
properties of hESC/iPSC-CMs are critical parameters to monitor.
Microelectrode arrays (MEAs) provide a highly sensitive, non-invasive method to study the electrophysi-
ology of cardiomyocytes with spatiotemporal resolution. However, to date, the application of MEA to human 
cardiomyocytes has largely been limited by biologically undefined factors including 3D nature of embryoid body, 
sera from animals, and feeder cells isolated from mouse5. In this paper, using two-dimensional monolayer cul-
tures of hESC-CMs with media free of animal products, we present a hybrid method for real-time measurement 
of electrophysiological dynamics of human cardiogenesis that is compatible with existing MEA technologies. 
Combination of hESC/iPSC-CM monolayer culture and the MEA system enables accurate, real-time, and flex-
ible measurement of electrophysiological characteristics, thereby providing a versatile biological tool to analyze 
human heart development, understand disease mechanism, and assess the efficacy and toxicity of drugs.
Results
Molecular and cellular characterization of hESC-CMs. H9 and UCLA4 hESCs were grown and dif-
ferentiated as previously described12 and plated as a monolayer. To define the differentiation stages, marker gene 
expression was serially profiled (Fig. 1a). mRNA quantification suggests that mesodermal markers (Mesp1, Bry) 
were highest at day 2 (mesodermal precursor stage; MP stage). Cardiac progenitor marker, ISL1, reached its peak 
at day 5 (cardiac progenitor stage; CP stage). Spontaneous contraction starts at around day 7. By day 14, major 
cardiac structural proteins, ion channels, and gap junctions became strongly expressed (immature cardiomyocyte 
stage; CM stage). At this stage, ~90% of the cells were MF20+ cardiomyocytes with typical sarcomeric structures 
(Fig. 1b). hESC-CMs underwent further maturation after day 14 and became elongated and oriented perpen-
dicular to the lateral registration of sarcomeres by day 30 (Fig. 1c). α -actinin staining suggests that the Z-band 
becomes more aligned at later stages (Fig. 1c).
To examine the maturation level of late-stage hESC-CMs, the expression of marker genes at day 14 and day 28 
were examined. Cardiac maturation indices, such as the subtype ratio of enzymes (CK-M/B) and metabolic indi-
cators (GLUT4/1), progressively increased (Fig. 1d). However, the expression level of most contractile proteins 
(TNNT2, TNNI3), gap junction genes (GJA 3), or ion channel genes (HCN4) were not significantly upregulated 
in mRNA at day 28 compared to day 14 (Fig. 1d). Therefore, the mRNA expression profile was highly distinctive 
at early differentiation stages (days 2–14) but became less definitive at late maturation stages (days 14–28).
Validation of MEA culture. Taking advantage of the monolayer differentiation regimen, hESC-CMs were 
cultured on an MEA platform that enables real-time (up to 40,000 samples/sec), simultaneous acquisition of 
120-channels of spatially distributed electrical data from individual microelectrodes embedded in a cell culture 
device (Fig. 2a–c). Inadequate contact between cultured cells and the measurement electrodes resulted in signal 
amplitudes less than a pre-defined signal-to-noise ratio (4), making them indistinguishable from the background 
noise of the measurement system. Electrode channels in firm contact with the underlying cell monolayer acquired 
clearly distinguishable local field potential signals (Fig. 3a) that enabled examination of hESC-CMs maturation 
at the electrophysiological level by monitoring their steady and consistent beat signatures over 10 days when 
cultured on an MEA plate. Regular beat intervals ranging from 2–4 s with standard deviations below 0.0014 s 
(Fig. 3b) and field potential durations (FPDs) of approximately 0.3–0.4 s were observed throughout the differen-
tiation (Fig. 3c). Corrected FPD was also relatively stable (Fig. 3d).
Monitoring the field potential of hESC/iPSC-CMs following chemical compound administration has been 
reported and expected as a novel drug screening tool for cardiotoxicity. To validate the assay system, response 
to pharmacological interventions were examined by administration of canonical ion channel blockers E4031, 
TTX (tetrodotoxin), and Nifedipine (Fig. 4). Consistent with previous reports6, E4031, a K+ channel blocker, 
reduced the field potential amplitude and the beat interval in a concentration-dependent manner but had no 
impact on FPD (Fig. 4a,d,g). TTX, a selective Na+ channel blocker, induced an increase in the beat interval even 
at a remarkably low concentration with a concurrent trend of reduction in the amplitude and FPD (Fig. 4b,e,h). 
Nifedipine, a Ca2+ channel blocker with negative inotropic and chronotropic effects, showed a mild trend of 
reduction in the peak amplitude of field potential, a significant increase in the beat interval, and decrease in FPD 
(Fig. 4c,f,i), consistent with well-known clinical observations. Previous reports using hESCs showed a decrease 
in beat interval with Nifedipine36. These inconsistencies may be attributed to the specific details of differentiation 
regimens, relative condition of the cells, or inter-cell line difference. The observed reduction in peak amplitude in 
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response to E4031 was deemed statistically significant based on a p value of less than 0.05 in an analysis of vari-
ance (ANOVA). Trends observed for the reduction in peak amplitudes for TTX and Nifedipine were found to be 
statistically insignificant. Trends, both increases and decreases, in observed beat intervals for all three ion channel 
blockers were also statistically significant according to their representative p-values. These results suggest that our 
system facilitates an accurate and real-time measurement of the electrophysiological activity of hESC-CMs6,36.
Identification of pacemaking cells in the monolayer cardiac sheet. The combination of a confluent 
layer of hESC-CM and the large microelectrode array allowed for not only temporal, but also for spatial analysis 
of the electrical activity. The field potential propagation was characterized using the phase difference of each 
channel covered by the confluent layer of hESC-CM. Figure 5 shows representative field potential propagation 
waves at varying cell age from day 18 to 25. The propagating wave generates circular wave fronts. Analysis over a 
Figure 1. (a) mRNA relative expression over the time course of hESC differentiation toward cardiac lineages. 
The value is standardized to the peak value of the time points for each gene. (b) Immunofluorescent staining for 
α -actinin in red showing over 90% are positive for α -actinin (scale bar = 100 um) (c) Morphological changes in 
hESC-CMs over the time course. Representative optical images of hESC-CMs on MEA on Day 20 and Day 35 
(fluorescent staining: α -Actinin in green, nucleus in blue, scale bar = 10 um). (d) mRNA relative expression by 
qPCR standardized to the expression of day0 over the time course of cardiac differentiation/maturation.
Figure 2. (a) Microelectrode arrays (MEA) with 120 integrated TiN electrodes (30 μ m diameter, 200 μ m inter-
electrode spacing) were used to culture the 2D hESC-CMs. (b) Representative optical image of hESC-CMs on 
top of MEA. (c) Field potential signals were detected in electrodes which are in touch with the hESC-CMs.
www.nature.com/scientificreports/
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20-minute recording window showed a consistent propagation map, indicating that the pacemaking source was 
stable (Fig. 5a–d). However, the propagation map changed over days, indicating that the pacemaking source was 
not completely fixed over a long period (Fig. 5e–h,i).
The electrical activity of hESC-CMs was initialized by a small group of pacemaking cells and propagated to 
the surrounding cardiomyocytes via gap junctions. Assuming that the propagation waves originated from a point 
source, the contour of the activation map was approximated by a circle. Although the position of pacemaking cells 
may fall outside of the electrode array in the MEA platform (see Fig. 2), the location of pacemaking cells can be 
predicted using the radius of the curvature of the field potential. For example, the coordinates of the pacemaking 
cells shown in Fig. 5j were (1.5, 9.7), at the edge of the MEA electrodes.
Characterization of cardiac maturity and conduction velocity. The capacity to monitor spatiotem-
porally resolved local field potentials in real-time provides a readout for maturation of hESC-CMs during dif-
ferentiation. Consistent with a previous study30, the mean field potential amplitude increased rapidly (4–5 fold) 
up to day 26 (Fig. 6a). Furthermore, the maximal field potential upstroke (dV/dt max), indicative of the sodium 
channel activity, became progressively larger as the hESC-CMs maturate (Fig. 6b). During natural embryogenesis, 
cardiac conduction velocity increases as the heart maturates, with neonatal and adult cardiomyocytes showing 
~0.3 m/s and ~1 m/s, respectively. To examine whether conduction velocity increases during the maturation of 
hESC-CMs in this system, the conduction speed was calculated by analyzing the signal traveling distance and 
time lag. Analysis performed in both vertical and diagonal directions with respect to the pseudo pacemaking 
region (Fig. 6c) reveal a conduction speed at day 18 of approximately 35 mm/s. As the hESC-CMs maturated over 
subsequent days, conduction velocities increased up to a maximum of 120mm/s at day 28, a value indicative of 
functional immaturity relative to neonatal cardiomyocytes. Field potential amplitude, upstroke and conduction 
velocity were determined to be statistically significant based on p-values < 0.05 determined via ANOVA. In con-
trast to commonly utilized molecular signatures, electrophysiological parameters showed a clear progression of 
cardiac maturity during the differentiation stages between days 14 to 26. Thus, the combination of the monolayer 
culture platform and MEA facilitates comprehensive monitoring of the electrophysiological maturation process 
of hESC-CMs.
Figure 3. (a) Field potential features such as beat interval, field potential duration, amplitude, and local 
activation time (LAT) were extracted out of the signal sequences. On average, 100 out of 120 channels were 
selected to calculate the beat interval after the peak detection and experiments were performed in triplicate. 
(b) The beat interval was stable up to day 28–30 with a beat interval around 2 s. Starting from day 28, the beat 
interval of hESC-CMs became unstable and irregular. The standard deviation (δ ) of beat interval agreed with 
the beat interval trend. (c) The field potential duration (FPD) ranged from 0.2 s to 0.5 s and was relatively stable 
throughout the differentiation process. (d) The corrected FPD ( = FPD/[beat interval/1000]1/3; Fridericia’s 
formula) was also relatively stable ranging from 0.2 to 0.3.
www.nature.com/scientificreports/
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Discussion
The integration of a chemically-defined differentiation regimen with a monolayer culture of human pluripotent 
stem cell-derived cardiomyocytes and electrophysiological measurement on an MEA platform provides a direct 
method to examine the spatiotemporal dynamics of the electromechanical maturation in human cardiomyo-
cytes. Stem cell derived cardiomyocytes provide a powerful tool for human developmental biology, regenerative 
therapies, disease modeling, and drug discovery. However, the utility of MEA for the hESC/iPSC-CMs has been 
largely limited to disease modeling and drug assessment7,37–44. The monolayer culture method described here 
overcomes technical problems associated with the utilization of conventional 3D embryoid bodies, namely large 
inter-experiment variability due to inconsistency in their size, quality, and attachment to MEA surface. In addi-
tion, the use of animal sera and feeder cells often introduce additional variables to differentiation efficiency and 
functionality. Our chemically-defined regimen serves to further minimize experiment-to-experiment variabil-
ity12. In combination, our system enables the monitoring of electric signals over weeks from cells in direct con-
tact with electrodes, identification of pacemaking cells, and performance of computational analyses of localized 
voltage-type signal and position-dependent properties of electrical activity.
Utilization of this system has enabled a direct characterization of electrophysiological maturation in 
hESC-CMs. During the natural embryonic cardiogenesis, action potential amplitude, action potential upstroke, 
conduction velocity, and heart rate gradually increase as the fetal cardiomyocytes maturate. In vitro differentia-
tion of pluripotent stem cells recapitulates the natural developmental process. Our data suggest that hESC-CM 
differentiation shows the same trend of electrophysiological properties including field potential amplitude, dV/
dt max, and conduction velocity. Even though our differentiation protocol is ‘directed’ toward the cardiac lineage, 
Figure 4. Peak mean amplitude (a–c) and mean beat interval (d–f) of field potential of monolayer 
cardiomyocytes cultured in the presence of (a,d) E4031 (K+ channel blocker), (b,e) TTX (tetrodotoxin, Na+ 
channel blocker) and (c,f) Nifedipine (Ca2+ channel blocker). p-values are calculated by one-way ANOVA. Data 
are representative of at least 2 biological replicates.
www.nature.com/scientificreports/
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Figure 5. Field potential propagation, pacemaking and conduction velocity of the 2D hESC-CMs. (a–h) 
shows a representative activation map from day 19, 20, 21, 22, 25, 26, 28, 29, respectively. The activation map 
was consistent over the 20-minute recording window showing a stable pace making source, but the propagation 
map changed over days. (i) On day 23, a contour graph of the propagation wave was generated from the 
activation map. (j) The center of the propagation wavelet was identified by fitting the wavelet with a circle. The 
origin of the circle represented the location of the pacemaking cells. The pacemaking cells were located at the 
edge of the MEA.
Figure 6. (a) The field potential amplitude rapidly increased until day 23 and declined at day 27. The turning 
point agreed with that of the beat interval. (b) The field potential amplitude upstroke speed increased from 
15.3 μ V/ms at day 18 to 122.9 μ V/ms at day 26 and declined at day 27. (c) Conduction velocity was calculated at 
each day. There was an increment of conduction velocity as the development of hESC-CMs. Results from two 
samples were consistent.
www.nature.com/scientificreports/
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the differentiation of hESC-CMs follows the same developmental process at genetic and electrophysiological 
levels. Of note, the electrophysiological parameters show a progressive increase in the field potential amplitude, 
dV/dt, and conduction velocity (Fig. 6), while typical cardiac markers including TNNT2 and TNN13 do not show 
significant differences after day 14 (Fig. 1). Therefore, electrophysiological parameters appear to be more sensi-
tive indicators for the assessment of cardiomyocyte maturity than genetic parameters. Although our monolayer 
hESC-CMs display robust beating, the electrophysiological parameters indicate that monolayer hESC-CMs are 
less differentiated than cardiomyocytes generated via 3D embryoid bodies. For example, previous reports show 
dV/dt max of 2 V/second or higher45,46. The relative immaturity of hESC-CMs may be in part because the mon-
olayer condition is less physiological than the 3D environment. Possibly due to the immaturity or to the spatial 
resolution of electrode array, the wave fronts were not reorganized from circular to oval pattern as hESC-CMs 
differentiate. These limitations should be considered when applying the monolayer hESC-CM MEA system to 
analyses of human developmental biology, patient-specific disease mechanisms and drug discovery/assessment.
Looking ahead, the availability of high-throughput measurement platforms has proven to be highly advan-
tageous in basic and translational research. High-throughput optical readouts using voltage dyes, calcium dyes, 
or their combinations have demonstrated the utility of hESC/iPSC-CMs as a model system for such methods6,47. 
While our current system configuration cannot be directly utilized in high-throughput analysis, there is no fun-
damental barrier that precludes the development of such capabilities. In fact, monolayer culture facilitates the 
basic molecular and cell biology techniques including lipofection, viral infection, and microscopic observation 
in combination with the electrophysiological analyses described here. Further, when considering the reproduci-
bility and the versatility of the MEA platform coupled with ~90% cardiac efficiency in our monolayer culture, the 
development of high-throughput electrophysiological readouts represents a promising research direction. The 
accurate, real-time, and flexible method demonstrated in this study sets a new standard for electrophysiological 
analyses of hESC/iPSC-CMs with broad applicability in stem cell biology.
Methods
Microelectrode array measurements. hESC-CMs were maintained and differentiated as previously 
described12. At 16 days of age hESC-CMs were plated on uncoated, microelectrode arrays (MEAs) containing 
120 integrated TiN electrodes (30 μ m diameter, 200 μ m interelectrode spacing). The MEAs were placed in an 
incubator with a temperature of 37 °C and 5% CO2. Two days were given to ensure the cardiomyocytes were well 
attached to the MEA. Recording commenced at a cell age of 18 days. Local field potentials at each electrode were 
collected over a period of 20 minutes, twice a day, and 3 weeks in total with a sampling rate of 1 KHz using the 
MEA2100-HS120 system (Multichannel systems, Reutlingen, Germany). The chemical compounds used herein 
were purchased from Tocris (E4031), Fisher Scientific (TTX) and Sigma-Aldrich (Nifedipine).
Peak detection. Determining the amplitude, frequency, and conduction velocity of cardiomyocyte activity 
required reliable assignment of peaks in the local field potential signal for all 120 channels. The Matlab function 
‘findpeaks’ was used with tunable parameters ‘minpeakheight’ and ‘minpeakdistance’ to reliably determine signal 
peaks. Setting the ‘minpeakheight’ as 16 μ V defined a minimum signal-to-noise ratio of 4 considering the noise 
level in the MEA system was ± 8 μ V. The ‘minpeakdistance’ was set as 1000 ms, which was based on the experi-
mental observation that cardiomyocytes were beating at a frequency smaller than 1 Hz.
Beat interval. The beat interval was measured as the peak-to-peak time difference from the beat amplitude 
assignments for each channel. After implementing peak detection as described above, the beat interval and stand-
ard deviation were collected for all channels. Unsynchronized and/or significantly noisy electrodes excluded from 
analysis were those with standard deviations that fell outside of 10% of the median standard deviation from all 
channels. The mean of the beat interval ± STD was calculated from all channels within this threshold.
Analyses of the field potential propagation. Time differences in the rhythmic local field potential col-
lected from 120 electrodes were quantified by dividing the complete data set for each day into a sequence of seg-
ments (typically 30 s, each). Peak detection was used to identify active channels. Cross correlation of the acquired 
signals from each active channel with respect to a pre-chosen reference electrode provided the time lag of each 
electrode with respect to the reference electrode. The time lags were then normalized between 1 and 0, represent-
ing the pace leader and last follower, respectively.
Identification of pacemaking cells. The pacemaking cells sometimes fall outside the region of the MEA 
electrode area. Assuming the whole cardiomyocyte culture had only one cluster of pacemaking cells and the 
pace-generating signal propagated like a wave, the position of the pacemaking cells can be extrapolated based on 
the partial propagation waveform that was detected in the MEA electrode area. Compared to the localized pace-
making cells, a contour plot of propagation time at each channel within the MEA electrode area was shown. Each 
archer-shape line had the same propagation time. A circle was fitted to the archer-shape line and the origin of the 
circle represented the location of the pacemaking cells. A Matlab circle fit module developed by Izhak Bucher was 
adopted in the above process.
Conduction speed analysis. Conduction speed was defined as the velocity of the field potential propa-
gation across the MEA surface. The time for each electrical beat was found through the peak detection analysis 
described previously. The time lag and distance of each channel with respect to the pacemaking cells (earliest beat 
identified from the 120 channels) was calculated. The conduction speed at each channel was therefore calculated. 
Conduction speed in both the vertical and diagonal direction was shown in Fig. 6c. To calculate the average 
conduction speed for each recording period, the conduction speed was averaged in both 120 channels and the 
20-minute recording period. Results from a cell age of 18 days to 25 days were shown in Fig. 6.
www.nature.com/scientificreports/
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